INVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Arrowhead Pharmaceuticals, Inc.
Investors
Law Offices of Howard G. Smith announces an investigation on behalf of investors of Arrowhead
Pharmaceuticals, Inc. (“Arrowhead” or the “Company”) (NASDAQ: ARWR) concerning the Company and its officers’ possible violations of federal securities laws.
Arrowhead is a biopharmaceutical company that develops novel drugs to treat intractable diseases in the United States.
On November 8, 2016, Arrowhead disclosed that the United States Food & Drug Administration (“FDA”) will be placing a
clinical hold on the Company’s Heparc-2004 clinical study of ARC-520. According to Arrowhead, the FDA’s clinical hold is likely due
to deaths at the highest dose of an ongoing non-human primate toxicology study.
On this news, Arrowhead stock has fallen as much as 30% during intra-day trading on November 9, 2016.
If you purchased Arrowhead securities, have information or would like to learn more about these claims, or have any questions
concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of
Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at 215-638-4847, toll-free
at 888-638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161109006393/en/